JW (Cayman) Therapeutics Co. Ltd (2126.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
281
First IPO Date
November 03, 2020
| Name | Title | Pay | Year Born |
| Feng Tian | CEO & Executive Director | 39,356 | 1978 |
| Min Liu | Chief Executive Officer & Executive Chairman | 2.05M | 1973 |
| Yiping Li | Co-Founder & Director | 6.49M | 1964 |
| Ka Man Ng | Company Secretary | 0 | 1978 |
| Jihua Qin | Vice President and Head of Marketing & Medical Affairs | 0 | 1980 |
| Zhen Xia | Head of Clinical Science Department | 0 | 1980 |
| Chunan Chen | Senior Vice President | 0 | 1974 |
| Mark J. Gilbert | Senior Advisor & Acting Chief Medical Officer | 0 | 1961 |
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.